fda import alert glp-1 semaglutide tirzepatide green list Food and Drug Administration Launches “Green List” for Drug FDA-Approved Dosages and Indications for

Real-world comparison of GLP-1 and metformin for PCOS: low one-year adherence, differing costs, side effects, and benefits of combination therapy.

- Formulated for Absorption & Now Easier to Swallow

Coverage Baseline Previously unavailable under Medicare Part D Only 13 states cover them in Medicaid (KFF HMA survey) 19% of large employers cover GLP-1s for obesity, though 43% of employers with 5,000+ employees offer coverage (KFF 2025 survey) Current Expansion ~50% of CVS Caremark clients now provide coverage for weight loss Medicare GLP-1 Bridge program launches coverage for eligible Medicare Part D patients 7/1/26 This aligns with a recent survey from Business Group on Health that found 67% of the surveyed employers now cover GLP-1s for weight loss (though a reduction is expected for 2027)

These recommendations are based on their potential benefits and how they can complement GLP-1 therapy to enhance health outcomes

Extending this work, the research team posed as a secret shopper to purchase GLP-1RAs from previously surveyed websites and collected information about the prescription process and the extent of clinician involvement